Protagonist Therapeutics, Inc.
NASDAQ:PTGX
Overview | Financials
Company Name | Protagonist Therapeutics, Inc. |
Symbol | PTGX |
Currency | USD |
Price | 41.49 |
Market Cap | 2,472,721,020 |
Dividend Yield | 0% |
52-week-range | 21.43 - 48.89 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Dinesh V. Patel Ph.D. |
Website | https://www.protagonist-inc.com |
An error occurred while fetching data.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD